01Impact factor
Impact factor of Transfusion Medicine and Hemotherapy (2026)
The impact factor shown here is the 2-year mean citedness: citations received in a year by the papers Transfusion Medicine and Hemotherapy published in the two previous years, divided by the number of those papers. That is the same formula as the Journal Impact Factor, calculated by ScholarsColab. The journal is listed in JCR 2024, so it also has an official Journal Impact Factor published by Clarivate, which can differ because it counts citations from Web of Science journals only.
Rank in its subject categories
- Hematologyrank 52 of 104 journals
- Immunologyrank 136 of 189 journals
Ranks here compare journals of the same Web of Science category in our data by 2-year citedness; they are not the official JCR rank.
Quartile of Transfusion Medicine and Hemotherapy
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Transfusion Medicine and Hemotherapy is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Citations and papers per year
Open access (listed in DOAJ); article processing charge listed at about US$1,670.
Is your paper a fit for Transfusion Medicine and Hemotherapy?
Most desk rejections come from a scope mismatch. Compare your title and abstract with what this journal really publishes. Free, no sign-up, about 2 minutes.
Check my paper for this journalOr find journals that fit my paper
Need a faster review? The fastest journals in Immunology accept papers in a median of 14 days.
- HLA 14 days
- Immunological Reviews 33 days
- Clinical and Experimental Vaccine Research 40 days
APC waivers and discounts for Transfusion Medicine and Hemotherapy APC about US$1,670
Karger: waiver or discount for low and lower-middle income countries; percentages are not published.
02Retractions
Retractions and research integrity at Transfusion Medicine and Hemotherapy
Most common reasons (a retraction can have several):
Transfusion Medicine and Hemotherapy has 2 retracted papers on record, the latest in Jul 2015. A retraction count is not a verdict on a journal: large journals publish more and journals that investigate actively retract more. The trend and the reasons tell you more than the number.
03Funders
Who funds research published in Transfusion Medicine and Hemotherapy
A high share of funded papers usually means the journal is a common choice for grant-supported work in its field. If your funder pays article processing charges, or your country qualifies for a waiver, check what applies to your author team with the free APC waiver checker.
04Indexing
Indexing of Transfusion Medicine and Hemotherapy
- ISSN
- 1660-3796
- eISSN
- 1660-3818
- Publisher
- Karger Publishers all its journals →
- Subjects
- Hematology, Immunology
From the indexing lists used on ScholarsColab, updated 1 March 2026. Indexing can change: confirm on the Web of Science Master Journal List or the Scopus source list before submitting. Official Journal Impact Factors and JCR quartiles are published by Clarivate; the impact factor on this page is calculated by ScholarsColab (see how the impact factor works).
- Web of Science Master Journal List
- SCImago Journal Rank
- ISSN Portal (ISSN 1660-3796)
- DOAJ (Directory of Open Access Journals)
Each link opens the official record for this journal, searched by its ISSN where we have one.
05How to submit
How to submit to Transfusion Medicine and Hemotherapy
- Read the guide for authors. It sets the article types, word limit, reference style and file format that Transfusion Medicine and Hemotherapy accepts. You find it on the official website of the journal, usually under "For authors" or "Submit".
- Format to the journal's style. Check whether it wants a Word file, a LaTeX file or a PDF for the first submission, and follow its reference style; many journals accept any clear format at first and ask for their style only after acceptance.
- Check the fit. Read the aims and scope and a few recent issues; papers outside the scope are the most common reason for a desk rejection. The Journal Finder shows journals that published the closest work.
- Plan the fee. Transfusion Medicine and Hemotherapy is fully open access, with an article fee of about US$1,670 after acceptance. See whether your author team qualifies for a waiver with the free APC waiver checker.
- Check your manuscript before you submit. The free Submission Readiness Check asks the seven questions our reviewers ask in every audit and takes about 2 minutes.
06Reviewer comments
Reviewer comments and rejection reasons for Transfusion Medicine and Hemotherapy
No reviewer or editor comments have been shared for this journal yet. Did you submit here? Help other researchers by sharing the comments you received, anonymously.
Share reviewer comments for this journal →Across the reviewer comments researchers have shared with us, the points raised most often are figures, tables and equations (21%), literature and references (12%) and novelty and contribution (10%). Before you submit to Transfusion Medicine and Hemotherapy, a Manuscript Audit by a PhD reviewer in your area checks your paper against exactly these points.
Audit my paper before I submit →Worried about the English? Manuscript editing by editors in your subject: see the price →
Not sure yet? Check if your paper is ready for this journal: free, no AI, under 5 seconds07Same subject
Hematology journals with a similar impact factor*
The journals next to Transfusion Medicine and Hemotherapy when the 103 journals of Hematology in our data are ranked by impact factor*:
| Rank | Journal | Impact factor* | Indexing | Open access |
|---|---|---|---|---|
| 48 | Acta Haematologica | 1.92 | SCIE | Subscription |
| 49 | Transfusion Medicine Reviews | 1.86 | SCIE | Subscription |
| 50 | Journal of Hematology | 1.83 | ESCI | Subscription |
| 51 | Transfusion | 1.82 | SCIE | Subscription |
| 53 | Blood Purification | 1.78 | SCIE | Subscription |
| 54 | Clinical and Applied Thrombosis/Hemostasis | 1.78 | SCIE | Fully open access |
| 55 | Leukemia & lymphoma/Leukemia and lymphoma | 1.76 | SCIE | Subscription |
| 56 | Journal of Blood Medicine | 1.75 | ESCI | Fully open access |
*Impact factor calculated by ScholarsColab (2-year citedness), not the official Clarivate value.
Is Transfusion Medicine and Hemotherapy right for your paper? Find the right journal
Paste your title, keywords or abstract. See the journals that published the closest papers, with indexing, impact factor, review time and APC.
No AI or language model is used. Your words are matched against the titles of 157,115 real published journal papers, by our mentors and by other researchers (shown without names); journals are ranked by how many closely matching papers they published. Indexing comes from the SCIE, SSCI, AHCI, ESCI, Scopus and JCR 2024 lists, matched by journal name; the impact factor is calculated by ScholarsColab, not the official Clarivate value, and no quartile is shown until the official JCR or SJR quartile can be; review time is the median days from submission to acceptance (not every publisher publishes these dates). Always check a journal’s scope and current indexing before submitting.
08Questions
Frequently asked questions
What is the impact factor of Transfusion Medicine and Hemotherapy?
Based on ScholarsColab citation data (October 2026), the 2-year impact factor of Transfusion Medicine and Hemotherapy is 1.80: papers it published in the two previous years were cited 1.80 times on average in a year. The journal is listed in JCR 2024, so Clarivate also publishes an official Journal Impact Factor, which can differ.
What is the h-index of Transfusion Medicine and Hemotherapy?
The h-index of Transfusion Medicine and Hemotherapy is 71 (October 2026): 71 of its papers have each been cited at least 71 times. Its i10-index is 645.
What is the APC of Transfusion Medicine and Hemotherapy?
The listed article processing charge (APC) is about US$1,670 for Transfusion Medicine and Hemotherapy, an open access journal (data from October 2026). APCs change and can differ by article type, country or discounts, so confirm the current charge on the journal’s website before submitting.
What is the quartile of Transfusion Medicine and Hemotherapy?
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Transfusion Medicine and Hemotherapy is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Is Transfusion Medicine and Hemotherapy indexed in Scopus?
Yes. Transfusion Medicine and Hemotherapy appears in the Scopus list, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Transfusion Medicine and Hemotherapy an SCIE journal?
Yes. Transfusion Medicine and Hemotherapy is listed in the Science Citation Index Expanded (SCIE), according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Transfusion Medicine and Hemotherapy in Journal Citation Reports (JCR)?
Yes. Transfusion Medicine and Hemotherapy is listed in JCR 2024, so it has a Journal Impact Factor. For the current impact factor and quartile, check Journal Citation Reports.
Does Transfusion Medicine and Hemotherapy offer an APC waiver?
Transfusion Medicine and Hemotherapy follows the policy of Karger: waiver or discount for low and lower-middle income countries; percentages are not published. Only the corresponding author's affiliation counts. Co-authors from other countries do not change the waiver. Rules verified 27 October 2026; confirm on the publisher's page.
Has Transfusion Medicine and Hemotherapy retracted papers?
Yes. 2 retracted papers are on record for Transfusion Medicine and Hemotherapy, 0 of them in the last 10 years; the most common reasons are concerns/issues about data, unreliable results and/or conclusions, duplication of/in article. A retraction count alone is not a verdict on a journal; look at the trend and the reasons. Data updated October 2026.
Who funds research published in Transfusion Medicine and Hemotherapy?
0% of 97 recent research articles in Transfusion Medicine and Hemotherapy name a funder.
Popular journals
- The Lancet
- Nature
- Science
- PLoS ONE
- Scientific Reports
- Journal of the American Chemical Society
- Journal of Organometallic Chemistry
- Electronics Letters
- Analyst
- Physical Review B
- European Journal of Pharmacology
- Journal of Chemical Physics
- Angewandte Chemie
- Food Chemistry
- Medicine
- Biochemistry
- Frontiers in Microbiology
- Energy
- British Journal of Surgery
- Journal of Molecular Structure
Browse all journals: indexing, impact factor and reviewer comments →